QUEBEC CITY – CrakRevenue announced today that it has increased the payout for BlueChew, a prescription chewable for treating erectile dysfunction (E.D.), to $80 per sale through June 15.
Axel Vézina, Chief Strategy Officer for CrakRevenue, said the payout increase is a reflection of the product’s performance, which has outpaced even the company’s most optimistic revenue projections.
“BlueChew has exceeded all of our wildest expectations in terms of sales,” Vézina said.
In a release announcing the increased payout, CrakRevenue reported that what “began as a simple web marketing success story” has become CrakRevenue’s top-converting product in the affiliate program’s history – and it reached that point in less than a year.
“I think that the overall success of BlueChew resides in the fact that this cure for erectile dysfunction uses the exact same active ingredients as Viagra, at a fraction of the price,” said Olivier Bourque, VP of Business Development at CrakRevenue. “I think that the current market climate was designed for BlueChew: It’s no longer considered your old man pill, with young adults turning to this product more and more. It has become more socially acceptable than ever.”
According to CrakRevenue, the E.D. treatment market amounts to $5 billion a year in the U.S. alone and presents a massive marketing opportunity for adult affiliates, as the appeal of E.D. products spans the division between adult and mainstream audiences.
“BlueChew generates sales on both adult and mainstream traffic,” Bourque said. “It’s the perfect crossover product for affiliates looking for new revenue streams.”
For more information on BlueChew and promoting the product through Crak Revenue, visit this page.
